Buy Adbry (tralokinumab-ldrm) Online For Sale
DISEASE INDICATIONS: Atopic Dermatitis
MANUFACTURER: Leo Pharma
MEDICINE APPROVED BY:
Food and Drug Administration (FDA)
Adbry is a medication that helps treat moderate-to-severe eczema. It is an injectable drug that blocks the activity of IL-13, which is a cytokine responsible for inflammation in eczema. A healthcare provider or trained patient/caregiver should administer the recommended dosage of 300 mg subcutaneously. Clinical studies have shown improvement in the symptoms of eczema.
Adbry (tralokinumab-ldrm) is a prescription medication that is used to treat moderate-to-severe eczema in patients aged 18 years and older. It is an injectable drug that can be self-administered subcutaneously.
Adbry belongs to a class of drugs called interleukin 13 (IL-13) inhibitors.
Adbry is indicated for the treatment of moderate-to-severe eczema in adult patients who are candidates for systemic therapy.
Mechanism of Action:
Eczema is a chronic inflammatory skin condition that is believed to be caused by various factors, including immune system dysfunction. Adbry works by blocking the activity of IL-13, which is a cytokine that plays an important role in the inflammation associated with eczema.
Dosage and Administration:
The recommended dosage of Adbry is 300 mg, administered subcutaneously every 2 weeks for the first three doses, followed by every 4 weeks thereafter. The medication should be administered by a healthcare provider or by a trained patient/caregiver.
Clinical studies have shown that treatment with Adbry can significantly improve the signs and symptoms of eczema, including itchiness, skin lesions, and overall disease severity.
The most common side effects of Adbry include injection site reactions, such as pain, redness, and swelling. Other possible adverse effects include upper respiratory tract infections, headache, and nausea.
Adbry is contraindicated in patients with a known hypersensitivity to tralokinumab or any of its components. It should also not be used in patients with active tuberculosis, as it can increase the risk of reactivation of the disease.
2 prefilled syringes of 150 mg/mL, 2 x 2 prefilled syringes of 150 mg/mL